Date: 2016-09-26
Type of information: Nomination
Compound:
Company: Inotec AMD (UK)
Therapeutic area: Medical devices
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 26, 2016, Inotec AMD announced the appointment of Chad Bateman as its new Chief Executive Officer on 1 October 2016. Since raising its Series A round led by VC fund Amadeus Capital Partners, in April 2016, Inotec AMD has strengthened its sales teams across a number of key territories and has appointed Shona Macdonald as Business Director for UK and Ireland. Ms Macdonald has many years of experience in the wound care market, having most recently been Business Director – UK & Ireland at Molnlycke.
Inotec AMD is a maker of mobile medical devices designed to heal chronic, hypoxic wounds that afflict millions of sufferers around the world every year. The global wound-care market is projected to grow to $18.3 billion globally in 2019, driven in part by changing life styles and ageing populations in many countries. There are some 400 million diabetes sufferers around the world, some 60 million of whom are likely to develop a lower limb ulcer. As more than 90% of wounds suffer from a lack of oxygen, the launch of Natrox™ addresses this serious concern with a simple, cost-effective application which treats a broad spectrum of chronic health problems.
Chad Bateman brings on board a proven track record of driving profitable revenue growth. Most recently, he was Vice President & General Manager - Europe and a member of the extended global leadership team of Acelity, a global leader in wound care and regenerative medicine. Chad has more than twenty years’ experience in sales and marketing, working in organisations such as Olympus and CR Bard Inc., the last seven years of which have been in senior executive positions within the wound care industry where he is highly regarded in the sector.
Financial terms:
Latest news:
